Skip to main content

C-RAD AB: Successfull evaluation at University Medical center Mannheim

Press release 2011-10-13

Press release 2011-10-13


Successful evaluation of C-RAD systems at the University Medical Center Mannheim


C-RAD AB with its four fully owned subsidiaries are all active in the field of radiation therapy. Clinical evaluation of the C-RAD Sentinel system was presented at the ASTRO meeting in Miami 2-4 October 2011.

In October 2010 two Sentinel systems were installed at the department of Radiation Oncology of University Medical Center Mannheim (UMM). The evaluation has been running in close cooperation with the Swedish companies Elekta and Oncolog Medical. The study was based on 67 fractions applied for the head and neck, thorax and pelvis regions. Analyzed parameters were three translation planes (lateral, longitudinal and vertical) of optical scans with C-RAD Sentinel versus Elekta cone beam CT system and rotation along the three axis. The study showed good agreement between the Sentinel system and cone beam CT system. Sentinel therefore holds potential to ensure precise patient positioning with reduced cone beam CT frequency in tumor locations with fixed relation to surface structures.

As a result of the study the parties have agreed to extend the study also to include the new advanced C-RAD Catalyst system.

The Department of Radiation Therapy and Radiation Oncology at the University Medical Center Mannheim has been active in the application and improvement of advanced treatment techniques such as IGRT, IMRT, VMAT and IORT. Through the use of the most advanced radiation therapy technology available, the Mannheim Center has become one of the most important treatment facilities for cancer patients in the Rhein- Neckar area, treating 2 300 to 2 400 patients per year.

The department has four linacs on site and a collaboration with two units off site. All systems are paper and filmless


Prof. Dr. Frank Lohr, UMM:

"We are looking forward to continue our studies based on the new Catalyst System and the cooperation with C-Rad. Due to the new algorithms used in the Catalyst Software we expect to improve the patient positioning accuracy for lower abdominal, pelvic and thoracic treatments and see great potential for the surveillance of breath-hold/gated treatments. The Catalyst concept with real time measurement, back projection and non-rigid-registration is very promising."


Erik Hedlund, CEO, C-RAD AB:

"The department of Radiation Oncology at University Medical Center Mannheim is one of the most recognized centers in Germany. The report presented by UMM and their interest also to extend the study to include the new Catalyst system is very encouraging. As a result we are expecting the first orders from the German market before end of the year."


For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46 (0)18  66 69 31, E-mail


Close Menu